SCHEMBL887130

SCHEMBL887130

CC(=O)n1cc(C)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 4/20 0.55
BRPF1 P55201 1/20 0.55
BRD9 Q9H8M2 1/20 0.55
HTT P42858 2/20 0.54
BAZ2B Q9UIF8 1/20 0.52
POLB P06746 4/20 0.52
ALDH1A1 P00352 5/20 0.51
KDM4E B2RXH2 4/20 0.51
HPGD P15428 1/20 0.51
HSD17B10 Q99714 1/20 0.51
TFPI2 P48307 1/20 0.50
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
S1PR4 O95977 1/20 0.48
S1PR1 P21453 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27887683 0.86 TFPI2 (0.51) CREBBPBRPF1BRD9HTTPOLB
SCHEMBL2594979 0.85 TFPI2 (0.54) CREBBPBRPF1BRD9POLBALDH1A1
SCHEMBL30622597 0.85 TFPI2 (0.54) CREBBPBRPF1BRD9POLBALDH1A1
SCHEMBL8530590 0.83 TFPI2 (0.49) CREBBPBRPF1BRD9HTTPOLB
SCHEMBL18856031 0.83 TFPI2 (0.49) CREBBPBRPF1BRD9HTTBAZ2B
SCHEMBL1333179 0.81 HTT (0.54) CREBBPBRPF1BRD9HTTBAZ2B
SCHEMBL887129 0.81 HTT (0.54) CREBBPBRPF1BRD9HTTBAZ2B
SCHEMBL14301382 0.80 KMT2A (0.61) HTTPOLBALDH1A1KDM4ETFPI2
SCHEMBL28477612 0.80 TFPI2 (0.47) POLBALDH1A1KDM4ETFPI2MEN1
SCHEMBL8076273 0.80 KMT2A (0.67) POLBALDH1A1KDM4ETFPI2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160331725-A1 USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS VEIJLEN N.V. 2016-11-17 US claimed
JP-4641942-B2 2011-03-02 JP claimed
EP-1670444-A2 USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES Veijlen N.V. (AN) 2006-06-21 EP claimed
WO-2005039546-A2 USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES VEIJLEN N.V. (AN) 2005-05-06 WO claimed
US-6881727-B2 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. (JP) 2005-04-19 US claimed
EP-1486207-A2 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. (JP) 2004-12-15 EP claimed
US-20030225043-A1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. 2003-12-04 US claimed
US-20030139379-A1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same SHIONOGI & CO., LTD. 2003-07-24 US claimed
EP-0950656-A1 SULFONATED AMINO ACID DERIVATIVES AND METALLOPROTEINASE INHIBITORS CONTAINING THE SAME SHIONOGI & CO., LTD. (JP) 1999-10-20 EP claimed
US-20240115626-A1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES CHURCH & DWIGHT CO., INC. (US) 2024-04-11 US disclosed
US-11801273-B2 Compositions and methods to increase production of isothiocyanates CHURCH & DWIGHT CO., INC. (US) 2023-10-31 US disclosed
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2023-09-28 US disclosed
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2023-09-28 US disclosed
CN-111170924-B Method for electrochemically synthesizing hexafluoroisopropoxyindole compound 广西师范大学 2023-06-30 CN disclosed
EP-0950656-A1 SULFONATED AMINO ACID DERIVATIVES AND METALLOPROTEINASE INHIBITORS CONTAINING THE SAME SHIONOGI & CO., LTD. (JP) 1999-10-20 EP disclosed
EP-0460679-B1 Endothelin antagonistic peptide derivatives BANYU PHARMA CO LTD (JP) 1998-10-28 EP disclosed
US-5691315-A CARDIOVASCULAR DISORDERS; VASODILATOR; BRONCHODILATOR BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-11-25 US disclosed
US-5470833-A Vasodilators, bronchodilators BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-11-28 US disclosed
US-5444152-A Vasolidator or bronchodilator BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-08-22 US disclosed
US-3950327-A NEW NITRONES, THEIR MANUFACTURE AND THEIR USE FOR THE MANUFACTURE OF N-SUBSTITUTED ARALIPHATIC ALDEHYDE-NITRONES CIBA-GEIGY CORPORATION (US) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139379-A1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same MMP9, MMP2, MMP1 CREBBP 3058/4885BRPF1 3518/4885BRD9 1760/4885
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, OPRL1 CREBBP 1300/4885BRPF1 3385/4885BRD9 2193/4885
US-20030225043-A1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same MMP9, MMP2, MMP1 CREBBP 3058/4885BRPF1 3518/4885BRD9 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.